Linked Life Data

7911736

Source:http://linkedlifedata.com/resource/pubmed/id/7911736

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1994-7-18
pubmed:abstractText
Cladribine (2-CdA, 2-chlorodeoxyadenosine), a chlorinated adenosine analog, is active in the treatment of hairy cell leukemia and other hematologic malignancies, but its use in treating solid tumors is still under investigation, as is the optimal schedule for administering this drug. The authors conducted a dose-finding study to define the maximal tolerated dose and toxicities of this agent when given to patients with refractory solid tumors having normal renal, hepatic, and bone marrow function.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0008-543X
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
74
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
168-73
pubmed:dateRevised
2010-3-24
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
A phase I study of intermittent infusion cladribine in patients with solid tumors.
pubmed:affiliation
Department of Medicine, University of Chicago Cancer Research Center, Illinois.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Controlled Clinical Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I